mRNA combination vaccine for seasonal flu and COVID-19 in adults 65–85

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 interventional study will give healthy or medically stable adults aged 65–85 different doses of an investigational mRNA combination flu/COVID-19 vaccine or licensed comparator vaccines. Participants will be monitored for safety and side effects and will have blood samples taken at scheduled visits to measure immune responses against influenza and SARS‑CoV‑2. Some groups will receive a licensed seasonal influenza vaccine or a licensed COVID‑19 vaccine to provide comparison data. Follow-up visits will record adverse events, clinical exams, and laboratory results to characterize tolerability and preliminary immunogenicity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol independently or with the assistance of the caregiver.
2. Informed consent obtained from the participant prior to performance of any study-specific procedure.
3. A male or female 65 to 85 years of age (YoA) (inclusive) at the time of screening.
4. Healthy participants or medically stable patients as established by medical history and clinical examination.
5. Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

1. Any clinically significant laboratory abnormality.
2. History of symptomatic influenza/ SARS-CoV-2 infection confirmed by local health authority-approved testing methods within 180 days (for influenza) or 90 days (SARS-CoV-2 infection) prior to study intervention administration.
3. History of Guillain-Barré syndrome (GBS) within 6 weeks of receiving any vaccine.
4. Current or past malignancy, unless completely resolved without clinically significant sequelae (e.g., no evidence of disease following successful treatment of basal cell carcinoma cases are allowed) for \>5 years.
5. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
6. History of or current suspicion of myocarditis or pericarditis (including following administration of an mRNA vaccine); or idiopathic cardiomyopathy, or presence of any medical condition that increases the risk of myocarditis or pericarditis, including cocaine abuse, cardiomyopathy, endomyocardial fibrosis, hypereosinophilic syndrome, hypersensitivity myocarditis, eosinophilic granulomatosis with polyangiitis and persistent myocardial infection.
7. History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
8. Acute or unstable chronic conditions, clinically significant pulmonary, cardiovascular, or renal functional abnormality, as determined by physical examination and/or laboratory screening tests.
9. History of hypersensitivity or allergic reaction to any previous influenza or COVID-19 vaccine.
10. History of hypersensitivity or allergic reaction to any previous mRNA vaccine.
11. Administration of any influenza vaccine within 181 days before the study intervention administration (Day -180 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
12. Administration of a SARS-CoV-2 antigen-containing vaccine in the period starting 91 days before the study intervention administration (Day -90 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
13. Administration of any mRNA-based vaccine in the period starting 29 days before the study intervention administration (Day -28 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
14. Administration of any other vaccine not foreseen by the study protocol in the period starting 29 days (Day -28 to Day 1) before the study intervention administration or planned administration within 28 days (Day 29) after the study intervention administration.
15. Other protocol-defined exclusion criteria may apply.

Where it's running

• GSK Investigational Site
  Anniston, Alabama, United States Recruiting
• GSK Investigational Site
  Little Rock, Arkansas, United States Recruiting
• GSK Investigational Site
  Fair Oaks, California, United States Recruiting
• GSK Investigational Site
  San Diego, California, United States Recruiting
• GSK Investigational Site
  Miami, Florida, United States Recruiting
• GSK Investigational Site
  Miami Lakes, Florida, United States Recruiting

Study contacts

• Study coordinator: US GSK Clinical Trials Call Center
• Email: GSKClinicalSupportHD@gsk.com
• Phone: 877-379-3718

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Influenza vaccine based on mRNA in adults 18-64

  A vaccine made with mRNA is being tested in adults 18 to 64 to see if it triggers a good immune response and is safe.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Glendale, Arizona and 11 other locations · NCT07851246

• Baloxavir for preventing flu after exposure in household contacts

  A single dose of baloxavir marboxil is being tested to see if it prevents symptomatic, lab-confirmed influenza in people who live with someone who has flu symptoms.

  Recruiting at 8 sites Phase 3 Hoffmann-La Roche · Guangzhou, Guangdong and 7 other locations · NCT07827599

• Influenza vaccine study for adults 65 and older

  A vaccine trial tests an investigational mRNA flu shot against a licensed flu vaccine in adults 65+ to see if it better prevents flu during the season.

  Recruiting at 163 sites Phase 3 GlaxoSmithKline · Anniston, Alabama and 162 other locations · NCT07805707

• Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure

  This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.

  Recruiting at 2 sites University Hospital of Cologne · Cologne and 1 other locations · NCT07721649

• Testing a new quadrivalent influenza vaccine for safety and effectiveness

  This study is testing a new flu vaccine to see if it's safe and effective for adults aged 18 and older.

  Recruiting Phase 1/2 Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Shijiazhuang, Hebei · NCT06824519

• Evaluating a new treatment to prevent severe COVID-19 complications

  This study is testing a new treatment to see if it can help hospitalized COVID-19 patients avoid severe complications caused by inflammation.

  Recruiting at 3 sites Phase 1/2 Peaches Biotech · Alcalá de Henares, Madrid and 2 other locations · NCT06684379

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.